Bluestar Genomics Commercializes Pancreatic Cancer Test
Bluestar Genomics has announced its U.S. and international commercialization of a test for early detection of pancreatic cancer.
Bluestar Genomics has announced its U.S. and international commercialization of a test for early detection of pancreatic cancer.
Bluestar Genomics’ liquid biopsy test can detect a pancreatic cancer signal in people across various age groups and in patients with new-onset diabetes.
cfDNA-based liquid biopsy analysis of KRAS mutations using OncoBEAM technology can assist in the prognosis determination and management of PDAC patients.
Some women may benefit from risk assessment, counseling, and testing for rare genetic mutations, says USPSTF.
Read MoreUpdated guidelines from the National Comprehensive Cancer Network recommend genetic testing for all patients with pancreatic cancer.
Read MoreThe partnership will focus on analysis of the circulating proteome of advanced pancreatic cancer patients, using the Biodesix Diagnostic Cortex machine-learning platform.
Read MoreAn Okayama University study reports the utility of identifying PD-L1 status at the time of diagnosing pancreatic cancer and demonstrates that fine-needle aspiration can be useful in facilitating such diagnoses.
Read MoreEarly results suggest the test can help expand the population of patients who can benefit from BRCA testing.
Read MoreIn a recent study, the company’s IMMray biomarker signatures achieved accuracy greater than 90% when diagnosing CCP-negative rheumatoid arthritis patients compared to healthy controls.
Read MoreImmunovia’s serum biomarker microarray detects pancreatic cancer in the early stages of development with 96% accuracy.
Read MoreThe PanFAM-1 study is designed to validate Immunovia’s IMMray PanCan-d assay, the first blood-based test for early detection of pancreatic cancer.
Read MoreDesigned to validate Immunovia’s blood-based test for familial pancreatic cancer risk, the study will analyze more than 1,000 individuals across sites in the United States and Europe.
Read MoreOrtho Clinical Diagnostics has launched the Vitros Immunodiagnostic Products C-Peptide reagent pack and calibrators, which broadens the company’s menu of tests for all aspects of diabetes and other pancreatic disorders.
Read MoreThermo Fisher Scientific has expanded its Oncomine portfolio with new assays for liquid biopsy and immunooncology.
Read MorePresenting an evaluation of the GeneReader next-generation sequencing (NGS) system, the article assesses the performance of the system in comparison with an alternative NGS technology.
Read MoreThis month’s issue features laboratory reagents and consumables from such companies as Audit Microcontrols, Bio-rad Laboratories, and Diasorin Molecular.
Read MoreThe proof-of-concept study, done in collaboration with researchers at the University of Heidelberg, provides evidence for using DiviTum as a dynamic biomarker before and during therapy to give important answers regarding prognosis and therapy efficacy.
Read MoreThe instrument utilizes an automated digitally assisted process to isolate clinically relevant cells from formalin-fixed paraffin-embedded tissue slides.
Read More